Table 3. Univariate Cox proportional hazards model analysis of OS in individuals with NSCLC.
| Variables | P value | HR | 95% CI |
|---|---|---|---|
| Age, years (≥65, <65) | 0.068 | 1.584 | 0.967–2.595 |
| Sex (female, male) | 0.431 | 1.236 | 0.730–2.092 |
| Adjuvant therapy (chemo-radiotherapy, none) | 0.003 | 4.002 | 1.611–9.940 |
| BMI, kg/m2 (≥22.5, <22.5) | 0.457 | 1.198 | 0.744–1.927 |
| Tobacco (no, yes) | 0.554 | 1.152 | 0.721–1.841 |
| COA-NLR (0, 1, 2) | <0.001 | 2.242 | 1.641–3.063 |
| GPS (0, 1, 2) | <0.001 | 1.905 | 1.351–2.686 |
| CRP, mg/dL (≥1, <1) | 0.141 | 1.422 | 0.890–2.272 |
| WBC, 109/L (≥6.6, <6.6) | <0.001 | 3.804 | 1.889–7.662 |
| Neutrophil, 109/L (≥3.7, <3.7) | <0.001 | 6.091 | 2.452–15.129 |
| Lymphocyte, 109/L (≥2.1, <2.1) | 0.051 | 0.620 | 0.383–1.003 |
| NLR (≥2.5, <2.5) | <0.001 | 2.492 | 1.548–4.011 |
| Hb, g/L (≥145, <145) | 0.198 | 0.681 | 0.379–1.223 |
| PLT, 109/L (≥200, <200) | 0.001 | 4.570 | 1.840–11.351 |
| Alb, g/L (≥35, <35) | <0.001 | 2.674 | 1.651–4.329 |
| ALT, U/L (≥20, <20) | 0.031 | 1.676 | 1.049–2.679 |
| LDH, U/L (≥138, <138) | 0.153 | 1.459 | 0.869–2.451 |
| Glucose, mmol/L (≥6, <6) | 0.019 | 1.922 | 1.112–3.320 |
| Pathologic N stage (N0, N1, N2, N3) | <0.001 | 2.518 | 1.574–4.028 |
| Pathologic T stage (T1, T2, T3, T4) | 0.001 | 2.820 | 1.544–5.152 |
| Metastasis (no, yes) | 0.004 | 2.960 | 1.415–6.191 |
| TNM status (I, II, III, IV) | <0.001 | 1.953 | 1.546–2.467 |
OS, overall survival; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval; BMI, body mass index; COA-NLR, combination of albumin concentration and neutrophil-to-lymphocyte ratio; GPS, Glasgow prognostic score; CRP, C-reactive protein; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; Hb, hemoglobin; PLT, platelet; Alb, albumin; ALT, alanine transaminase; LDH, lactate dehydrogenase; TNM, tumor-node-metastasis.